METHOD FOR THE PREPARATION OF 21-HYDROXY-6,19-OXIDOPROGESTERONE (21OH-6OP)
A 21-Hydroxy-6,19-oxidoprogesterone derivative of Formula (1): where R is —C(O)—CH 2 CH 3 , —C(O)—(CH 2 ) 2 —COOH, —C(O)—(CH 2 ) 7 —CH═CH—(CH 2 ) 7 —COOH, or —C(O)—PO 3 Na 2 .
1 - 13 . (canceled)
14 . A 21-hydroxy-6,19-oxidoprogesterone ester of Formula (1):
wherein R is selected from the group consisting of —C(O)—CH 2 CH 3 , —C(O)—-(CH 2 ) 2 —COOH, —C(O)—(CH 2 ) 7 —CH═CH—(CH 2 ) 7 —COOH, and —C(O)—PO 3 Na 2 .
15 . The 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 , wherein R is —C(O)—CH 2 CH 3 .
16 . The 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 , wherein R is —C(O)—(CH 2 ) 2 —COOH.
17 . The 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 , wherein R is —C(O)—(CH 2 ) 7 —CH═CH—(CH 2 ) 7 —COOH.
18 . The 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 , wherein R is —C(O)—PO 3 Na 2 .
19 . A composition comprising the 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 and a pharmaceutically acceptable carrier.
20 . A method of preparing the composition of claim 19 , comprising mixing the 21-hydroxy-6,19-oxidoprogesterone ester and the carrier to form the composition.
21 . At method of treating a disease resulting from an excess of glucocorticoid in a patient in need thereof, comprising
administering the 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 to the patient in an amount sufficient to treat the disease.
22 . The method of claim 21 , wherein the disease is selected from the group consisting of Cushing's syndrome, iatrogenic hypercoticolism, depression, and a combination thereof.
23 . The method of claim 22 , wherein the disease is Cushing's syndrome.
24 . The method of claim 22 , wherein the disease is depression.
25 . The method of claim 22 , wherein the disease is iatrogenic hypercoticolism.
26 . A method of treating a clinical manifestation of Cushing's syndrome selected from the group consisting of hypertension, renal calculi, osteoporosis, glucose intolerance, muscle wasting, reduced resistance to infection, psychiatric disturbances, and combinations thereof, in a patient in need thereof, comprising administering the 21-hydroxy-6,19-oxidoprogesterone ester of claim 14 to the patient in an amount sufficient to treat the clinical disease manifestation.
27 . The method of claim 26 , wherein the clinical disease manifestation is hypertension.
28 . The method of claim 26 , wherein the clinical disease manifestation is renal calculi.
29 . The method of claim 26 , wherein the clinical disease manifestation is osteoporosis.
30 . The method of claim 26 , wherein the clinical disease manifestation is glucose intolerance.
31 . The method of claim 26 , wherein the clinical disease manifestation is muscle wasting.
32 . The method of claim 26 , wherein the clinical disease manifestation is reduced resistance to infection.